1Riely GJ, Politi KA, Miller VA, et al. Update on epidermal groxah factor receptor ntations in non-small cell lung cancer [ J ], Clin Cancer Res, 2006, 12(24):7232-7241. 被引量：1
2Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status[J]. Lung Cancer, 2010, 68(2) :198-203. 被引量：1
3Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non- small-cell lung cancer [ J ]. J Clin Oncol, 2012, 30 ( 4 ) : 433 -440. 被引量：1
4Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) [J]. J Thorac Oncol, 2014, 9(2):154-162. 被引量：1
5Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[ J]. Nature, 2007, 448(7153) :561-566. 被引量：1
6Zhang X, Zhang S, Yang X, et al. Fusion of EMLA and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression [J]. Mol Cancer, 2010, 9:188. 被引量：1
7Zhang NN, Liu YT, Ma L, et al. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy[ J]. PLoS One, 2014, 9 ( 1 ) : e84501. 被引量：1
8Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations[J]. J Clin Oncol, 2008, 26(15) :2442-2449. 被引量：1
9Mitsudnmi T, Morita S, Yatabe Y, et al. Gefitlnib versus eisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WYrOG5405): an open label, randnmised phase 5 trial [ J ]. Lancet Oncol, 2010, 11 (2) : 121-128. 被引量：1
10Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation- positive non-small-cell lung cancer (OPTIMAL, CTONG-0802 ) : a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oneol, 2011, 12 ( 8 ) : 735-742. 被引量：1
